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NF-κBn (rv-cyclin) of walleye dermal sarcoma virus contains two known functional
domains, a cyclin box motif and a carboxy terminal transcription activation domain (AD). The AD contacts
TATA-binding protein-associated factor 9 (TAF9), and this action is necessary for both positive and negative
regulation of transcription from host and viral promoters. Negative regulation occurs via interference with
TAF9 binding by transcriptional activators. Transcription factors that share a functional TAF9-binding motif
include NF-κB. Rv-cyclin down regulates NF-κB-dependent transcription, whether induced by TNFα or by
direct phosphorylation of IκB by expressed MEKK1. In rv-cyclin-expressing cells, NF-κB p65 is
phosphorylated and translocated to the nucleus, where it forms heterodimers with p50 and binds NF-κB
response elements. Furthermore, interference with NF-κB is dependent upon an intact TAF9-binding motif in
rv-cyclin. The outcome of this NF-κB down regulation is likely to be important in the control of virus
replication and tumorigenesis.
© 2009 Elsevier Inc. All rights reserved.IntroductionWalleye dermal sarcoma virus (WDSV) is a complex retrovirus
etiologically associated with dermal sarcomas in walleye ﬁsh (Sander
vitreus) (Martineau et al., 1992, 1991; Walker, 1969; Yamamoto et al.,
1985,1976). The seasonal nature of dermal sarcoma is characterized by
low levels of spliced accessory gene transcripts, A1 and B, during tumor
development and high levels of full-length and spliced transcripts
during tumor regression (Bowser et al., 1988, 1996; Bowser and
Wooster, 1991; Martineau et al., 1991; Quackenbush et al., 1997;
Rovnak et al., 2001). Infectious virus is only found in regressing tumors.
The A1 transcript encodes a retroviral cyclin (rv-cyclin, Orf A
protein), which contains a cyclin box motif and a transcription
activation domain (AD) (LaPierre et al., 1998; Rovnak et al., 2005). Rv-
cyclin localizes in the nucleus where it is associated with active
transcription complexes and with cofactors of transcription including
components of the Mediator complex (Rovnak et al., 2001, 2005;
Rovnak and Quackenbush, 2002, 2006). Rv-cyclin inhibits transcription
from theWDSV promoter in luciferase reporter systems, andmutations
within the AD diminish this activity (Rovnak et al., 2005; Rovnak and
Quackenbush, 2002; Zhang and Martineau, 1999). The rv-cyclin AD
directly interacts with TATA-binding protein-associated factor 9 (TAF9)
(Rovnak and Quackenbush, 2006). The herpes simplex virus transcrip-
tion factor, VP16, also binds TAF9, and rv-cyclin blocks VP16/TAF9
interaction both physically and functionally (Choi et al., 2000; Rovnak
andQuackenbush, 2006;Uesugi et al.,1997). In addition to VP16 and rv-(S.L. Quackenbush).
l rights reserved.cyclin, seven other transcription factors are known to contain the
conserved TAF9 binding motif, FXX∅∅, one of which is the NF-κB
subunit, p65 (Choi et al., 2000; Uesugi and Verdine, 1999). NF-κB
regulates a wide array of genes involved in inﬂammatory, anti-
apoptotic, and immune responses. The NF-κB family is comprised of
ﬁvemembers, p50, p52, p65 (Rel A), Rel B, and c-Rel (recently reviewed
in (Hayden and Ghosh, 2008). Each member contains a Rel homology
domain (RHD) near theN-terminus of the protein that is responsible for
the formation of homo- and heterodimers, nuclear localization, and
DNA binding. p65, Rel B, and c-Rel have transcription activation
domains located in their C-terminus. Inactive NF-κB is sequestered in
the cytoplasm in a complexwith IκB. Upon exposure of cells to a diverse
array of stimuli, IκB is phosphorylated and targeted for degradation
resulting in the release of NF-κB from the complex. NF-κB is post-
translationally modiﬁed and translocated to the nucleus where it binds
to promoter sequences of target genes to activate their transcription.
Most viruses have evolved strategies to inﬂuence the NF-κB
signaling pathway (recently reviewed in Hiscott et al., 2006).
Transcription of some viruses, such as human immunodeﬁciency
virus (HIV) and cytomegalovirus (CMV), is dependent on NF-κB
activation and binding to NF-κB consensus sites in the viral
promoters. Persistent activation of the NF-κB pathway in Epstein
Barr virus (EBV) infection and transduction of c-rel by an avian
retrovirus are associated with tumor formation. Many viruses encode
proteins that inhibit NF-κB and interfere with the innate immune
response. Inhibition of NF-κB signaling by viral proteins may occur at
numerous steps in the transduction pathway. For example, adeno-
virus type 12 E1A inhibits phosphorylation of NF-κB, and African
swine fever virus protein, A238L, prevents acetylation of p65 (Granja
et al., 2008; Guan et al., 2008).
Fig. 2. WDSV rv-cyclin inhibits NF-κB transcription after TNFα treatment. HeLa cells
were co-transfected with a NF-κB-luciferase reporter vector (pNF-κB-luc), a control
expression vector, pKH3 (white bars), or rv-cyclin expression vector, pKH3-rv-cyclin
(black bars), and Tk promoter-Renilla vector (pRL-Tk). Cells were treated with TNFα at
24 h post-transfection and harvested 5 h later. Results are reported as mean±standard
deviation of the ratio of luciferase activity versus Renilla activity from quadruplicate
wells.
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transcription via its TAF9 binding motif as observed previously with
VP16 transcriptional activation (Rovnak et al., 2005; Rovnak and
Quackenbush, 2006). In this study, we show that the rv-cyclin AD
functions to inhibit NF-κB p65-dependent transcription.
Results
Rv-cyclin inhibits NF-κB-dependent transcription in both HeLa and
walleye cell lines
Previous studies showed that rv-cyclin affects transcription from
various promoters and that this regulation is due, in part, to the
interaction of the rv-cyclin AD with TAF9 (Rovnak et al., 2005; Rovnak
and Quackenbush, 2002, 2006). The AD of NF-κB p65 has also been
reported to bind TAF9 (Buss et al., 2004; Lu and Levine, 1995; Uesugi
and Verdine, 1999). Therefore, we evaluated the effects of rv-cyclin on
NF-κB-dependent transcription.
HeLa cells and the walleye cell line, W12, were co-transfected
with an NF-κB luciferase reporter vector (pNF-κB-luc) and a
plasmid encoding constitutively active MEKK1 (pFC-MEKK).
MEKK1 phosphorylates IκBα, targeting it for degradation, which
results in the release of NF-κB (Lee et al., 1997). Over-expression of
MEKK1 resulted in 182- and 5-fold activation of transcription from
the NF-κB reporter construct in HeLa and W12 cells, respectively.
No increased activation was observed in cells transfected with
control vector, pFC (Figs. 1A and B). However, in cells co-transfected
with a plasmid encoding rv-cyclin (pKH3-rv-cyclin) and MEKK1,
signiﬁcant inhibition of NF-κB-dependent transcription in HeLa cells
(11.8 fold) and W12 cells (5.8 fold) was evident (P≤0.001) (Figs. 1A
and B).
To further evaluate the effect of rv-cyclin on NF-κB-dependent
transcription, cells were treated with tumor necrosis factor alpha
(TNFα), a known inducer of NF-κB signaling cascade. Treatment of
HeLa cells with TNFα resulted in activation of luciferase expression
from the NF-κB reporter, and again expression of the rv-cyclin
signiﬁcantly reduced NF-κB-dependent transcription 2.2 fold
(P≤0.001) (Fig. 2).Fig. 1. WDSV rv-cyclin inhibits NF-κB-dependent transcription in HeLa and walleye
cells. HeLa cells (A) andwalleyeW12 cells (B) were co-transfectedwith NF-κB-luciferase
reporter vector (pNF-κB-luc), control or MEKK expression vectors (pFC or pFC-MEKK),
and control or rv-cyclin expression vectors (pKH3 (white bars) or pKH3-rv-cyclin (black
bars)). A Renilla expression vector with a thymidine kinase promoter (pRL-Tk) was also
included. Results are reported as mean±standard deviation of the ratio of luciferase
activity versus Renilla activity from triplicate wells. The data presented in this ﬁgure are
representative of four independent experiments.WDSV rv-cyclin does not affect phosphorylation or nuclear localization
of p65
Treatment of cells with TNFα activates the IKK complex
resulting in phosphorylation and degradation of IκBα. NF-κB
p65 is then phosphorylated and translocated to the nucleus.
Studies by Buss et al. (Buss et al., 2004) showed that binding of
NF-κB p65 to TAF9 was favored by phosphorylation of serine 536
(p65-Ser536).
We established an rv-cyclin-inducible cell line (HeLa Tet-Off/
myc-rv-cyclin). Uninduced and induced cells were either left
untreated or were treated with 15 ng/ml of TNFα. Whole cell
lysates were assayed by western blot with a phospho-speciﬁc NF-κB
p65 antibody, which showed that p65 was phosphorylated on
residue Ser536 after TNFα treatment regardless of whether rv-
cyclin was present (Fig. 3A). Likewise, analysis of nuclear extracts
from TNFα-treated cells demonstrated successful nuclear transloca-
tion of p65 in the presence or absence of rv-cyclin (Fig. 3B).
Together, these data exclude rv-cyclin interference with Ser536
phosphorylation and nuclear translocation as mechanisms of
transcription inhibition.Fig. 3. WDSV rv-cyclin does not affect phosphorylation or nuclear translocation of NF-
κB p65. (A) Whole cell lysates from cells with or without induced rv-cyclin expression
and untreated or treated with 15 ng/ml TNFα were examined by western blot. Blots
were probed with the indicated antibodies: anti-p65 and anti-p65-Ser536 (phospho-
serine 536). (B) Nuclear extracts from untreated or TNFα-treated cells with or without
induced rv-cyclin expression were probed for p65, β-actin and rv-cyclin.
Fig. 5. Mutation of rv-cyclin AD at Val260 affects the inhibition of NF-κB-dependent
transcription. HeLa cells were co-transfected with a NF-κB-luciferase reporter vector
(pNF-κB-luc), pFC or pFC-MEKK constructs, and control vector, pKH3 (white bars), or
pKH3-rv-cyclinwild type (WT) or rv-cyclin ADmutations (V260F or V260S) (black bars).
A Renilla expression vector with a thymidine kinase promoter (pRL-Tk) was also
included. Results are reported as mean±standard deviation of the ratio of luciferase
activity versus Renilla activity from quadruplicate wells. The data presented in this
ﬁgure are representative of two independent experiments.
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Electrophoretic mobility shift assays (EMSA) were employed to
evaluate whether rv-cyclin inhibition of NF-κB-dependent transcrip-
tionwas due to an affect on NF-κB-DNA binding. Nuclear extracts from
cells with or without induced rv-cyclin expression and TNFα
treatment (Fig. 3B) were incubated with a κB speciﬁc probe, and the
resulting complexes were separated on a non-denaturing polyacryla-
mide gel. Very little binding to the κB-speciﬁc probewas observedwith
nuclear extracts from cells without TNFα treatment (Fig. 4A, lanes 2
and 3). In contrast, nuclear extracts from cells treated with TNFαwith
or without induced rv-cyclin expression formed a prominent protein-
DNA complex (Fig. 4A, lanes 4 and 5). The speciﬁcity of protein binding
to the NF-κB probe was demonstrated by competition with a 100-fold
molar excess of unlabeled NF-κB probe (Fig. 4A, lanes 6 and 8).
Competition of nuclear extract binding to the NF-κB probe was not
observed with an unlabeled Oct1 competitor probe (Fig. 4A, lanes 7
and 9). To assess the composition of the NF-κB binding complex,
formed after TNFα stimulation, nuclear extracts were incubated with
normal rabbit serum orwith polyclonal antiserum against p65, p50, or
rv-cyclin. When an antibody to NF-κB subunit, p50 or p65, was added
to nuclear extracts, the formation of a supershifted protein-DNA
complexwas observed (Fig. 4B, lanes 1, 2, 5, and 6). Addition of anti-rv-
cyclin or normal rabbit serum did not cause a supershift of the NF-κB-
DNA complex (Fig. 4B, lanes 3, 4, 7, 8). Anti-rv-cyclin sera is effective in
binding the native rv-cyclin protein (Rovnak et al., 2001, 2007; Rovnak
and Quackenbush, 2002, 2006). These results indicate that the
complex formed on the κB probe contains a p50/p65 heterodimer
and furtherdemonstrate that rv-cyclin is not associatedwith theNF-κB
that is bound to DNA and is not interferingwith NF-κB binding to DNA.
Mutations within the AD of rv-cyclin alter the inhibitory effects of
NF-κB-dependent transcription
Previous studies demonstrated that mutations within the AD of rv-
cyclin affected the function of rv-cyclin and its protein–protein interac-
tions (Rovnak et al., 2005; Rovnak and Quackenbush, 2006). To assessFig. 4.WDSV rv-cyclin does not affect binding of NF-κB to DNA. (A) Nuclear extracts from
untreated or from cells treated with TNFα and with or without induced rv-cyclin
expressionwere incubatedwith a 32P-labeledoligonucleotide containing a κBbinding site
(lanes 2–9), and the reactions separated on a 6% nondenaturing polyacrylamide gel for
autoradiography. Lane 1 contains oligonucleotide probe (P) alone. Unlabeled NF-κB probe
(competitor probe) was added to the reactions in lanes 6 and 8. Unlabeled Oct1 probe
(nonspeciﬁc competitor probe) was added to the reactions in lanes 7 and 9. (B) Nuclear
extracts from cells treated with TNFα and with or without induced rv-cyclin were
incubated with the κB binding site probe and anti-NF-κB p50 (p50) (lanes 1 and 5), anti-
NF-κB p65 (p65) (lanes 2 and 6), anti-rv-cyclin (rv) (lanes 3 and 7) or normal rabbit serum
(nr) (lanes 4 and 8). Reaction products were separated on a 6% gel for autoradiography.whether these AD mutations altered the effects of rv-cyclin on NF-κB-
dependent transcription, HeLa cells were co-transfected with the NF-κB-
luc reporter vector and pFC-MEKK1 and with either wild type rv-cyclin
(WT) or rv-cyclin containing mutations within the TAF9-bindingmotif at
valine 260, V260F or V260S. V260F is a conservative mutation that
maintains TAF9 binding and rv-cyclin function, and V260S is a loss-of-
function mutation (Rovnak and Quackenbush, 2006). The wild type rv-
cyclin signiﬁcantly inhibitedNF-κB-dependent luciferase activity to12%of
the activity found in cells that donot express rv-cyclin (control value set at
100% activity) (P≤0.01) (Fig. 5). Rv-cyclin with the conservative V260F
mutation signiﬁcantly reduced luciferase activity to 33% of control values
(P≤0.01) (Fig. 5). In contrast, rv-cyclin with the V260S mutation had no
signiﬁcant effect onNF-κB-dependent transcription. These results suggest
that the rv-cyclin TAF9-binding motif is primarily responsible for the
inhibitory effects on NF-κB-dependent transcription.
Expression of rv-cyclin AD interferes with the activation domain of
NF-κB p65
When fused to the GAL4 DNA binding domain (DBD), the p65
activation domain (p65AD416–551) activates transcription from a GAL4
luciferase reporter vector (pFR-luc) (Figs. 6A and B, white bars). The
isolated rv-cyclin ADwas localized to the nucleus by fusion to a nuclear
localization sequence (nls) in an expression construct, pKH3nls-rv-
cyclin240–270 (Rovnak and Quackenbush, 2006). Co-expression of the
rv-cyclin AD in cells with the GAL4DBD-p65AD416–551 construct
resulted in a signiﬁcant reduction in luciferase activity compared to
the activity in cells without rv-cyclin expression and titration of
pKH3nls-rv-cyclin240–270 demonstrated speciﬁc inhibition of the
activity of GAL4DBDp65AD416–551 (P≤0.001, 0.0 μg rv-cyclin240–270
versus 0.2 μg rv-cyclin240–270; P≤0.01, 0.0 μg rv-cyclin240–270 versus
0.1 μg rv-cyclin240–270) (Fig. 6A).
Further evaluation of the rv-cyclin AD's inhibitory effect on p65
activation of transcription was tested with mutations V260F and
V260S. AD-V260F inhibited GAL4DBD-p65AD activity to 20% of control
values (Fig. 6B). AD-V260S reduced the ability of the wild type rv-
cyclin AD to inhibit expression from the GAL4-luciferase reporter
construct to 64% of control. These results demonstrate that the rv-
cyclin AD is responsible for the inhibition of function of the p65 AD
and support a mechanism for inhibition that is dependent upon a
critical residue within the TAF9-binding motif of the rv-cyclin AD.
Over-expression of TAF9 partially restores NF-κB dependent
transcription in the presence of rv-cyclin
The data suggests that the TAF9-binding motif of the rv-cyclin is
functional in the inhibition of NF-κB-dependent transcription, and we
Fig. 7. Over-expression of TAF9 partially restores NF-κB dependent transcription in the
presence of rv-cyclin. HeLa cells were co-transfected with a NF-κB-luciferase reporter
vector (pNF-κB-luc), pFC or pFC-MEKK constructs, and control vector, pKH3 (white
bars), or pKH3-rv-cyclin wild type (WT) and the indicated quantities of expression
construct pKH3-hTAF9. A Renilla expression vector with a thymidine kinase promoter
(pRL-Tk) was also included. Results are reported as mean±standard deviation of the
ratio of luciferase activity versus Renilla activity from quadruplicate wells. The data
presented in this ﬁgure are representative of two independent experiments.
Fig. 6. The rv-cyclin AD interferes with the activation of transcription by GAL4-p65AD.
(A) HeLa cells were transfected with a GAL4-luciferase reporter construct (pFR-luc), a
vector expressing a GAL4-DNA binding domain fusion with NF-κB p65 AD amino acids
416–551 (pGAL4-p65416–551), and a control expression vector, pKH3 (white bars), or the
indicated quantities of expression construct pKH3-rv-cyclin240–270 (black bars) and pRL-
Tk. Results are reported as ratios of luciferase versus Renilla activity. (B) HeLa cells
transfected with GAL4 reporter vector (pFR-luc), pGAL4-p65416–551 fusion construct,
and control expression vector, pKH3 (white bars), pKH3-rv-cyclin240–270 wild type
(WT), or pKH3-rv-cyclin240–270 mutations (V260F or V260S) (black bars) and pRL-Tk.
Results are reported as mean±standard deviation of the ratio of luciferase activity
versus Renilla activity from quadruplicate wells. The data presented in this ﬁgure are
representative of two independent experiments.
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necessary NF-κB interaction with TAF9 via a common TAF9-binding
motif. Over-expression of TAF9 should reverse rv-cyclin inhibition of
NF-κB dependent transcription by occupying the rv-cyclin TAF9-
binding motif. However, excess TAF9 would be expected to bind both
NF-κB and rv-cyclin at and away from transcription sites, thereby
leading to overall inhibition of NF-κB-induced transcription with
increasing TAF9 concentrations. This effect was observed in control
preparations co-transfected with a TAF9 expression vector, pKH3TAF9.
There was however an apparent relief of the rv-cyclin-mediated
inhibition of NF-κB dependent transcription (1.9-fold increase,
P≤0.08, 0.0 μg TAF9 versus 0.013 μg TAF9; 2.5-fold increase, P≤0.01,
0.0 μg TAF9 versus 0.05 μg TAF9) (Fig. 7). These results further support
the role of the rv-cyclin TAF9-binding motif in the inhibition of
transcription promotion by other factors, which share this motif.
Discussion
These studies indicate that WDSV has developed a strategy to
manipulate the NF-κB signaling pathway by interfering with the
function of the p65 activation domain. Rv-cyclin inhibited an NF-κB
reporter genewhen cells were treatedwith TNFα orwhenMEKK1was
over-expressed. Binding of TNFα to its receptor leads to IKK activation,
and activated MEKK1 results in activation of the NF-κB pathway by
phosphorylation of IκBα (Lee et al., 1997; Zhao and Lee, 1999).Phosphorylation of IκBα results in its degradation and the release of
NF-κB. NF-κB is then phosphorylated and translocated to the nucleus
where it binds to target gene promoters. Viruses encode proteins that
affect NF-κB signaling at multiple positions in the pathway such as
blocking IKK activation or inhibiting IκB degradation or NF-κB
phosphorylation or DNA binding (recently reviewed in (Hiscott et al.,
2006). Increased levels of phosphorylated NF-κB p65 were found in
lysates from cells, with or without rv-cyclin, after treatment with
TNFα, and EMSA demonstrated that rv-cyclin did not affect the
formation of NF-κB p50/p65 heterodimers on a κB-speciﬁc probe.
PosttranslationalmodiﬁcationsofNF-κBp65regulate itsbinding to IκB
and its binding to κB sites in promoters and interactionswith coactivators
and repressors (Hayden and Ghosh, 2008). Phosphorylation at serine
residues 276 or 536 enhances the interaction of p65 with the histone
acetyltransferases, p300 and CBP, and results in acetylation of lysine 310,
which increases its transcriptional activity (Chen et al., 2005).We focused
our attentionon residue536, becauseNF-κBp65phosphorylated at serine
536 participates in binding to TAF9 (Buss et al., 2004), and the WDSV rv-
cyclin protein binds TAF9 (Rovnak and Quackenbush, 2006). Buss et al.
(2004) suggest that the hydrogen bond formed between Ser536 and
Asp533 regulates binding to either TAF9 or to the protein, amino terminal
enhancer of split (AES); Upon phosphorylation of Ser536 the hydrogen
bond is disrupted, and TAF9 binding is favored. In the absence of Ser536
phosphorylation, p65 preferentially binds AES, and AES represses NF-κB
transcriptional activity (Tetsuka et al., 2000). Exposure of cells to TNFα,
with or without rv-cyclin, resulted in phosphorylation of p65 Ser536,
indicating that p65 is in the correct context for binding to TAF9. A similar
mechanism, of phospho-regulationof binding toTAF9or to a co-repressor,
has been shownwithp53and theco-repressorMDM2(Jabburet al., 2002;
Uesugi and Verdine, 1999). MDM2 binding to the FXXΦΦ motif in p53
prevents binding to TAF9. Phosphorylation of p53 at residue Thr18
disrupts a hydrogen bond between Thr18 and Asp21 and attenuates
MDM2 interaction to facilitate recruitment of TAF9 (Jabbur et al., 2002;
Kussie et al., 1996; Uesugi and Verdine, 1999).
The phosphorylation of p65 at Ser536 and its subsequent interac-
tion with TAF9 has been shown to be required for transcription of
interleukin 8 (Buss et al., 2004), but recently, Sasaki et al. (Sasaki et al.,
2007) showed that phosphorylation of p65 Ser536was not required for
expression of Traf1. Their data suggested that the distance of the κB
response element from the transcription start site inﬂuences which
NF-κB-responsive genes are induced by phosphorylated and non-
phosphorylated p65. It is anticipated that this higher degree of NF-κB
gene regulation will inﬂuence the number and type of NF-κB-
responsive cellular genes that can be affected by rv-cyclin.
The wild type rv-cyclin AD and the conservative V260F AD
mutation inhibited the transcriptional activity of a GAL4-p65 AD
fusion protein, while the V260S AD mutation greatly reduced these
59S.L. Quackenbush et al. / Virology 386 (2009) 55–60inhibitory effects. These results are similar to those previously
observed with herpesvirus VP16 and with the WDSV promoter
(Rovnak et al., 2005; Rovnak and Quackenbush, 2002, 2006).
Interaction of rv-cyclin AD V260S with puriﬁed TAF9 was reduced in
pull down assays, suggesting that the inhibitory effect of rv-cyclin on
NF-κB-dependent transcription is due to competition for binding to
TAF9. However, the reductions of inhibition in the case of the
conservative V260F mutation (Figs. 5 and 6B) were unexpected
based on previous results, which demonstrated enhanced TAF9
binding with this mutation (Rovnak and Quackenbush, 2006) and
enhanced inhibition of the WDSV promoter in walleye ﬁbroblasts
(Rovnak et al., 2005). This variation indicates that factors in addition to
TAF9 interaction may be inﬂuencing the rv-cyclin inhibition of NF-κB-
induced transcription. We previously showed that a GST-rv-cyclin AD
fusion protein pulls down p300 and CBP from nuclear extracts and
could compete with VP16C for binding to p300 (Rovnak et al., 2005;
Rovnak and Quackenbush, 2006). It is possible that rv-cyclin binds
directly to p300/CBP and in turn blocks or alters interaction with p65
and affects its activity. An example of such a mechanism is the African
swine fever virus protein, A238L, which binds p300/CBP and inhibits
NF-κB acetylation and transcriptional activity (Granja et al., 2008).
Pursuit of such interactions will be the subject of future investigations.
These studies focused on the role of the rv-cyclin AD in NF-κB-
dependent transcription. However, we cannot rule out the contribu-
tion of the cyclin box motif and its affect on transcription. Rv-cyclin
interacts with cyclin-dependent kinase 8 (cdk8), a component of the
Mediator complex, (Rovnak et al., 2005; Rovnak and Quackenbush,
2002). The rv-cyclin/cdk8 interaction may affect the presence or
absence of the cdk8 module of Mediator at a speciﬁc promoter and
affect the eventual outcome, i.e. inhibition or activation of transcrip-
tion. The HIV promoter serves as an example of cdk8 association with
gene regulation; Studies by Kim et al. (Kim et al., 2006) demonstrate
that in cells harboring HIV, which has an NF-κB-regulated promoter,
the cdk8 module of Mediator is lost upon activation of transcription.
The combination of cdk8 function in the Mediator complex with TAF9
interference may further inﬂuence rv-cyclin's effects on individual
promoters. The work presented here extends our previous observa-
tions and suggests that the rv-cyclin AD, through binding to TAF9,
inhibits the binding of select transcription factors with TAF9-
dependent activation domains.
Activation of the NF-κB pathway is essential for the initiation of an
immune response, and is often a target for viral interference (Hiscott et
al., 2006). Type I interferon is themajor antiviral defensemechanism of
the innate immune response in mammals and ﬁsh. Viral infection of
host cells leads to the activation of transcription factors, NF-κB and
interferon regulatory factor (IRF), which are required for optimal
activation of IFN promoters. Type I IFN genes have been identiﬁed in
several species ofﬁsh and function inways similar tomammalian type I
IFNs (Robertsen, 2006;Whyte, 2007). We have tested a zebraﬁsh type I
IFN promoter reporter (zIFN-luc) in walleye cells and found that rv-
cyclin inhibited luciferase expression after induction with poly I:C
treatment (data not shown). These results support the hypothesis that
theWDSV rv-cyclin functions to inhibit the innate immune response in
infected cells.We have shownpreviously that the rv-cyclin also inhibits
transcription from the WDSV promoter in walleye ﬁbroblasts (Rovnak
and Quackenbush, 2002). This combination of immune interference
and suppression of viral antigen expression during the period of tumor
growth suggests a concerted effort to evade an effective immune
response to tumor development.
Materials and methods
Cells and generation of rv-cyclin inducible cell line
HeLa cells were maintained in Dulbecco's modiﬁed Eagle medium
at 37 °C in 5% CO2. W12 cells were maintained in Liebowitz 15 mediaat 20 °C in closed ﬂasks. All media was supplemented with 10% fetal
bovine calf sera (Gibco), 4 mM glutamine, 100 U penicillin ml−1, and
100 μg streptomycin ml−1.
The inducible rv-cyclin cell line was generated using the Tet-Off
Gene Expression System (BD Biosciences). WDSV rv-cyclin was sub-
cloned from the pKH3-OrfA vector into the pTRE-Myc vector at HindIII
and XbaI sites after modiﬁcation of termini of the open reading frame
by PCR. The HeLa Tet-Off cell line (BD Biosciences) was co-transfected
with pTRE-Myc-rv-cyclin and pTK-Hyg plasmids and selected with
G418 and hygromycin. Individual colonies were expanded and
screened for inducible expression of myc-tagged rv-cyclin when
cultured in the absence of doxycycline.
Plasmid constructs
All rv-cyclin clones have been described previously (Rovnak et al.,
2001, 2005; Rovnak andQuackenbush, 2006). The p65AD (a.a. 416–551)
was ampliﬁed by RT-PCR from HeLa cell RNA with forward primer,
CGGGATCCGGCCCTCCTCAGGCTGTGGC, and reverse primer, GGAATTCT-
TAGGAGCTGATCTGACTCAG, incorporatingBamH1andEcoR1 restriction
sites, respectively. After restriction digestion, amplicons were cloned
into theGAL4DNAbinding domain fusionvector, pFA-CMV (Stratagene).
Full-length human TAF9 was ampliﬁed by RT-PCR from HeLa cell RNA
and cloned into the expression construct pKH3 (pKH3-hTAF9). All
constructs were conﬁrmed by sequence analysis.
Reporter-gene constructs and luciferase assays
Cells seeded in 24-well plates were transfected with 0.3 μg of the
pNF-κB-Luc vector (Stratagene), 0.01 μg (W12) or 0.0001 μg (HeLa) of
pRL-TK plasmid (Promega), 0.05 μg pFC or pFC-MEKK (Stratagene),
and 0.05 μg pKH3 or pKH3-rv-cyclin wild type or pKH3-rv-cyclin
V260F or V260S using FuGENE6 (Roche) according to the manufac-
turers' suggestions. NF-κB-Luc contains ﬁve tandem repeats of the κB
consensus site upstream of the luciferase gene. pFC-MEKK expresses
constitutively activated MEKK1. Experiments were performed using
the dual-luciferase reporter assay system (Promega). Cell lysates were
harvested at 48 h (HeLa) or 72 h (W12) post-transfection with passive
lysis buffer and centrifuged at 20,000 ×g for 5 min at 4 °C. For TNFα
stimulation, 15 ng/ml of TNFα was added 24 h after transfection with
pNF-κB-luc, pRL-TK, and pKH3 or pKH3-rv-cyclin, and luciferase
activity was measured 5 h later. Luciferase activities were obtained
with a Beckman Coulter LD400 luminometer. Luciferase activity from
the reporter vector was normalized for transfection efﬁciency with
values from the co-transfected pRL-TK vector. All transfections were
performed in triplicate or quadruplicate. The data is presented as the
mean±standard deviation of the ratio of luciferase activity versus
Renilla activity. Student's t test and 95% conﬁdence intervals based on
a t distributionwere used for statistical analyses. A P value of less than
0.01 was considered signiﬁcant.
For assays of GAL4-DBD fusion constructs, cells were transfected
with 0.3 μg of pFR-Luc, 0.025 μg or pFA-CMV or pFA-p65AD416–551, and
0.2 μg pKH3nls, pKH3nls-rv-cyclin240–270, pKH3nls-rv-cyclin240–
270V260S, or pKH3nls-rv-cyclin240–270V260F using FuGENE6 (Roche)
according to the manufacturers' suggestions. The pFR-Luc reporter
vector (Stratagene) contains ﬁve tandem repeats of the yeast GAL4
DNA binding site upstream of the luciferase gene. Lysates were
harvested 48 h after transfection and luciferase activity was measured
as above.
Nuclear extracts and gel mobility shift assays
HeLa Tet-Off myc-tagged rv-cyclin cells were cultured in the
presence (uninduced expression) or absence (induced expression) of
2 μg/ml doxycycline and either left untreated or treated with 20 ng/
ml TNFα for 10 min. Nuclear extracts were prepared by hypotonic
60 S.L. Quackenbush et al. / Virology 386 (2009) 55–60lysis and KCl extraction of nuclei as previously described (Dignam et
al., 1983). A double-stranded NF-κB speciﬁc oligonucleotide probe (5′
AGTTGAGGGGACTTTCCCAGGC 3′) (Promega) was end-labeled with
γ-32P ATP and T4 polynucleotide kinase (New England Biolabs).
3.5 μg of nuclear extract and 1 μg poly (dI:dC) (GE Healthcare) were
added to EMSA reaction buffer (10 mM HEPES pH 7.9, 50 mM KCl,
2.5 mM DTT, 0.1 mM EDTA, 0.05% NP-40, and 10% (v/v) glycerol) in a
total volume of 20 μl and incubated for 10 min at room temperature.
20,000 cpm of labeled oligonucleotide probe was then added, and
incubated for another 20 min. Where indicated, 2 μg of antibody was
added after the incubation with probe, and the reaction was further
incubated at 4 °C for 1 h. Samples were then separated on a 6% DNA
Retardation Gel (Invitrogen) in 0.5X TBE (45 mM Tris-base pH 8.3,
45 mM Boric acid, 1 mM EDTA). The gels were run at 150 V for
45 min, dried and placed on x-ray ﬁlm at −80 °C. A double-stranded
Oct 1 oligonucleotide (5′ TGTCGAATGCAAATCACTAGAA 3′) (Pro-
mega) was used as a nonspeciﬁc competitor for EMSA.
Antibodies
Anti-myc (clone 9E10, sc-40), anti-p65 (H-286X), and anti-p50
(sc7178X) were supplied by Santa Cruz Biotechnology, Inc. Anti-NF-κB
p65 (#3034), anti-phospho-NF-κB p65 Ser 536 (#3036S) and β-Actin
(#4967) were from Cell Signaling Technology. Anti-Orf A antisera for
mobility shift assays and preimmune sera were previously described
(Rovnak et al., 2001).
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